https://gglabs.ejoinme.org/MyEvents/WalkAThon/Fundraising/tabid/1295576/Default.aspx?joinme=1888333In 2026, Provigil (modafinil) continues to be a cornerstone treatment for managing conditions that cause extreme daytime drowsiness, specifically narcolepsy, obstructive sleep apnea, and shift work disorder. Classified as a eugeroic, or wakefulness-promoting agent, it functions by subtly altering neurotransmitters in the brain's sleep-regulation centers—such as dopamine, orexin, and histamine—to keep the mind alert without the intense physical "jitters" common with traditional stimulants.